Literature DB >> 18201819

CpG dinucleotide methylation of the CYP19 I.3/II promoter modulates cAMP-stimulated aromatase activity.

Masashi Demura1, Serdar E Bulun.   

Abstract

Aromatase expression varies in a tissue-specific manner and among individuals. Aromatase promoter I.3/II, regulated by a cAMP response element (CRE), is normally quiescent in human skin fibroblasts, whereas its hyperactivity may cause local or systemic estrogen excess. We describe the methylation status of 6 CpG dinucleotides within a 571-bp fragment of promoter I.3/II containing a CRE in cAMP-responsive (n=1) or nonresponsive (n=3) primary skin fibroblasts cultured from healthy volunteers. Four out of 6 CpG dinucleotides were unmethylated in cAMP-responsive fibroblasts, whereas all 6 CpG dinucleotides were hypermethylated in cAMP-nonresponsive fibroblasts. Basal and cAMP-stimulated aromatase activity and promoter I.3/II activation were significantly higher in the presence of unmethylated DNA. Furthermore, methylation at the CRE interfered with CREB binding. Thus, methylation of CpG dinucleotides within promoter I.3/II regulates aromatase expression and may be one source of inter-individual variability. Furthermore, abnormal methylation of the aromatase promoter may contribute to aromatase overexpression in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18201819     DOI: 10.1016/j.mce.2007.12.003

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  18 in total

1.  DNA methylation and histone modifications are associated with repression of the inhibin α promoter in the rat corpus luteum.

Authors:  Kristen M Meldi; Georgia A Gaconnet; Kelly E Mayo
Journal:  Endocrinology       Date:  2012-08-03       Impact factor: 4.736

2.  Redundant enhancers and causal variants in the TCF7L2 gene.

Authors:  Edward A Ruiz-Narváez
Journal:  Eur J Hum Genet       Date:  2014-02-12       Impact factor: 4.246

Review 3.  Epigenetic regulation of the expression of genes involved in steroid hormone biosynthesis and action.

Authors:  Daniel B Martinez-Arguelles; Vassilios Papadopoulos
Journal:  Steroids       Date:  2010-02-13       Impact factor: 2.668

4.  Epigenetics meets endocrinology.

Authors:  Xiang Zhang; Shuk-Mei Ho
Journal:  J Mol Endocrinol       Date:  2011-02       Impact factor: 5.098

5.  Role of Ucp1 enhancer methylation and chromatin remodelling in the control of Ucp1 expression in murine adipose tissue.

Authors:  A Shore; A Karamitri; P Kemp; J R Speakman; M A Lomax
Journal:  Diabetologia       Date:  2010-03-18       Impact factor: 10.122

6.  Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas.

Authors:  Roger Gejman; Dalia L Batista; Ying Zhong; Yunli Zhou; Xun Zhang; Brooke Swearingen; Constantine A Stratakis; E Tessa Hedley-Whyte; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-07-15       Impact factor: 5.958

Review 7.  Endocrine disruption of the epigenome: a breast cancer link.

Authors:  Kevin C Knower; Sarah Q To; Yuet-Kin Leung; Shuk-Mei Ho; Colin D Clyne
Journal:  Endocr Relat Cancer       Date:  2014-03-12       Impact factor: 5.678

8.  Early onset pre-eclampsia is associated with altered DNA methylation of cortisol-signalling and steroidogenic genes in the placenta.

Authors:  Kirsten Hogg; John D Blair; Deborah E McFadden; Peter von Dadelszen; Wendy P Robinson
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

9.  Maternal separation is associated with strain-specific responses to stress and epigenetic alterations to Nr3c1, Avp, and Nr4a1 in mouse.

Authors:  R L Kember; E L Dempster; T H A Lee; L C Schalkwyk; J Mill; C Fernandes
Journal:  Brain Behav       Date:  2012-06-29       Impact factor: 2.708

10.  Use of alternative promoters may hide genetic effects on phenotypic traits.

Authors:  Edward A Ruiz-Narváez
Journal:  J Hum Genet       Date:  2012-10-04       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.